Key result
Adding hemosorption to drug therapy is linked to improved LVEF and lower NT-proBNP in severe HF.
Why the study?
Many patients with heart failure remain refractory to medical therapy, prompting evaluation of drug therapy combined with hemosorption for severe heart failure secondary to dilated cardiomyopathy.
Does hemosorption added to drug therapy improve NT-pro BNP levels and left ventricular function in patients with severe heart failure due to dilated cardiomyopathy?
Cohort (n=30)
Does hemosorption added to drug therapy improve NT-pro BNP levels and left ventricular function in patients with severe heart failure due to dilated cardiomyopathy?
The addition of hemosorption to standard drug therapy in patients with severe heart failure due to dilated cardiomyopathy significantly improves left ventricular systolic function and reduces NT-proBNP levels.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for conservative therapy in refractory HF; larger randomized trials needed before practice change.
Background. Heart failure (HF) is a complex cardiac pathology that is the main cause of hospitalisation among adults and is characterised by a high mortality. Dilated cardiomyopathy (DCM) is the most common cause of HF, and it can be fatal within a few years after the first symptoms appear. Many patients with HF remain refractory to medical therapy, despite its constant development and improvement. The study aims to compare the effectiveness of conservative treatment of patients with severe HF that occurred on the background of DCM using drug therapy and its combination with a course of hemosorption (HS). Materials and methods. We analysed treatment outcomes in 30 patients with severe HF against DCM (New York Heart Association class III–V, left ventricular ejection fraction (LV EF) < 30 %). Patients in group 1 (n = 13; N-terminal fragment of brain natriuretic peptide precursor (NT-pro BNP) 4,546.23 ± ± 3,265.01 pg/ml; LV EF 16.77 ± 2.92 %; LV end-diastolic volume (EDV) 261.31 ± 60.60 ml, LV end-systolic volume (ESV) 214.85 ± 49.44 ml) received drug therapy according to local protocols. In group 2 (n = 17; NT-pro BNP 3,974.49 ± 3,550.17 pg/ml; LV EF 18.18 ± 4.36 %; LV EDV 261.12 ± 79.96 ml, LV ESV 212.06 ± 71.67 ml), medical treatment was supplemented with a course of 3 HS procedures using granular deligandizing hemosorbent. Results. Patients in both study groups noted an improvement in well-being and a decrease in the severity of symptoms. The level of NT-pro BNP decreased to 2,609.92 ± 1,465.14 pg/ml (p < 0.01) in group 1 and to 975.35 ± 511.55 pg/ml (p < 0.05) in group 2. LV EF increased to 22.77 ± 4.69 % and 26.76 ± 5.02 %, respectively, in the groups (p < 0.01). In patients of group 1, LV EDV and LV ESV changed to 262.22 ± 40.92 ml and 211.33 ± 35.22 ml, respectively. In group 2, there was a significant decrease in LV EDV to 228.94 ± 73.16 ml and LV ESV to 170.88 ± 60.28 ml (p < 0.01). Conclusions. The use of HS in combination with drug therapy for severe HF on the background of DCM improves the clinical status of patients and LV systolic function.
No takes yet. Share an insight, caveat, or question.
K.V. Denysiuk (2024) conducted a cohort in Severe heart failure with dilated cardiomyopathy (n=30). Hemosorption (HS) in combination with drug therapy vs. Drug therapy according to local protocols was evaluated on NT-pro BNP level and left ventricular ejection fraction (LV EF). Supplementing drug therapy with hemosorption in patients with severe heart failure and dilated cardiomyopathy decreased NT-pro BNP to 975.35 pg/ml and increased LV EF to 26.76%.
Synapse has enriched 10 related papers. Consider them for comparative context: